{
    "symbol": "ORGS",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-21 16:08:09",
    "content": " We believe our strategy of decentralizing the supply of cell and gene therapies based on standardization of the manufacturing production environment will ultimately become the solution for this industry, enabling lower cost, streamlined logistics, accelerated development and providing a scalable long-term option to overcome the industry-wide capacity constraints. Cost of revenues, development services and research and development for the three months ended December 31, 2022 were $6.1 million and $27.1 million for the three months and 12 months ended December 31, 2022, a decrease of 43% and 26%, respectively, over the same period last year. In previous years, we made significant investments in research and development services, including in the development of several types of OMPULs, the development of automated processing units and processes, owned and licensed advanced therapies to enable commercial production and additional work that addresses POCare needs. Selling, general and administrative expenses for the three months ended December 31, 2022, were $6.8 million, compared to $2.7 million for the same period last year. Operating loss for the three months ended December 31, 2022, was $627,000, a decrease of 91%, compared to $6.9 million for the same period last year. Net loss for the three months ended December 31, 2022, was $1.3 million, a decrease of 75%, compared to $5 million for the same period last year."
}